Abbott Laboratories

New York Stock Exchange
Back to all articles
Bullish +75

Abbott (ABT) Stock Rated Buy on Strong Diabetes Trial Results

AI-generated analysis

📈 Benchmark reiterated a Buy rating for Abbott Laboratories (NYSE: ABT) and set a $145 price target following the FreeDM trial results.

💉 The FreeDM trial showed that Type 2 diabetes patients using continuous glucose monitoring technology achieved better glucose outcomes than those using fingerstick blood samples.

🇪🇺 Positive UK trial findings were supported by a second interventional trial conducted in Italy at the same conference.

⚠️ Results highlight a need for expanded insurance coverage of continuous glucose monitoring in European nations where it is not officially covered.

🇺🇸 CMS is considering expanding compensation for continuous glucose monitoring in the US, positioning Abbott to benefit from potential policy changes.

🏥 Abbott Laboratories is a global healthcare company manufacturing branded generic medications, medical devices, diagnostics, and nutritional items.

⚖️ Benchmark notes investment risks but maintains conviction that AI stocks may offer higher returns over shorter time frames compared to ABT.

🔗 The article concludes with links to related content regarding other stock picks and healthcare equipment recommendations from analysts.

Bullish Signals
  • Benchmark reiterated a Buy rating for Abbott Laboratories (NYSE: ABT) with a price target of $145 following encouraging results from the FreeDM trial.
  • The trial demonstrated that patients with Type 2 diabetes on basal insulin therapy achieved better glucose results using FreeStyle Libre continuous glucose monitoring technology compared to fingerstick blood samples.
  • A second interventional trial from Italy supported the UK findings, further validating Abbott's FreeStyle Libre technology and highlighting expansion opportunities in European nations.
  • Abbott is well-positioned to profit from potential CMS decisions to expand compensation for continuous glucose monitoring in the US.
Risk Factors
  • While Abbott receives a Buy rating for diabetes trial results, the article explicitly warns that some AI stocks hold greater promise for delivering higher returns in a shorter time frame.
  • The article suggests investors seeking significant upside potential should consider other 'AI stock' opportunities over ABT, noting a specific claim of 10,000% upside potential for an alternative stock instead.
  • Expansion of insurance coverage for continuous glucose monitoring in European nations is still pending and not officially covered in some regions, limiting Abbott's immediate profitability from this segment.
  • No decision on expanding CMS compensation in the US is expected 'very soon,' creating uncertainty around near-term revenue growth from this development.
Full Analysis
Abbott Laboratories (NYSE: ABT) continues to be highlighted as an attractive investment following positive clinical trial results for its FreeStyle Libre continuous glucose monitoring technology. On March 13, Benchmark reiterated a Buy rating for the company with a price target of $145 per share, citing strong data from a UK-based FreeDM trial involving patients with Type 2 diabetes on basal insulin therapy. The study found that individuals using FreeStyle Libre achieved superior glucose results compared to those utilizing traditional whole blood glucose meters with fingerstick samples. These findings were further corroborated by a separate interventional trial conducted in Italy, both of which underscore the growing demand for expanded insurance coverage for continuous glucose monitoring technology across European nations where it currently lacks official reimbursement. The article also notes that while no immediate decision is expected from U.S. regulators, the Centers for Medicare & Medicaid Services (CMS) is considering expanding compensation structures for such devices in the United States. Benchmark views Abbott Laboratories as well-positioned to capitalize on this potential policy shift, given its status as a leading global healthcare company and top provider of continuous glucose monitoring systems. Abbott's business portfolio spans branded generic medications, medical devices, diagnostics, and nutritional products, positioning it for diverse growth opportunities within the healthcare sector. However, the text includes a speculative promotional element suggesting that alternative AI stocks may offer greater upside potential than ABT in a shorter timeframe, implying a 10,000% upside opportunity in an unspecified AI stock report. The content concludes by providing various unrelated investment links and performance metrics for Insider Monkey's subscription service, noting returns since its inception in May 2014 through February 18th, 2026, while stating that the financial advice content is not affiliated with specific stock recommendations beyond the reiterated Buy rating for Abbott.